Dr. Reddy’s Laboratories Limited — Form 20-F Summary
Reporting period: Fiscal year ended March 31, 2024. The filing is an annual Form 20-F, not a standalone 2023 fourth-quarter filing. Financial statements are prepared under IFRS as issued by the IASB and presented in Indian rupees; U.S. dollar figures are unaudited convenience translations at Rs.83.34 per U.S. dollar.
Business context
Dr. Reddy’s is an India-based global pharmaceutical company operating through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others. Products include branded and unbranded generics, biosimilars, APIs, contract research and manufacturing services, OTC products, and digital and wellness offerings. Principal markets include the United States, India, Russia, Europe and other emerging markets.
- Global Generics generated 88% of consolidated revenue.
- PSAI generated 11% of consolidated revenue.
- Others generated 1% of consolidated revenue.
- Export revenue was Rs.230,691 million, or 83% of total revenue.
Key financial metrics
| Metric | FY2024 | FY2023 | Change |
|---|---|---|---|
| Revenue | Rs.279,164 million | Rs.245,879 million | +13.5% |
| Gross profit | Rs.163,607 million | Rs.139,343 million | +17.4% |
| Gross margin | 58.6% | 56.7% | +190 bps |
| Operating profit | Rs.67,729 million | Rs.57,144 million | +18.5% |
| Operating margin | 24.3% | 23.2% | +110 bps |
| Profit before tax | Rs.71,870 million | Rs.60,367 million | +19.1% |
| Net profit | Rs.55,684 million | Rs.45,067 million | +23.6% |
| Net margin | 19.9% | 18.3% | +160 bps |
| Basic EPS | Rs.334.65 | Rs.271.43 | +23.3% |
| Diluted EPS | Rs.334.02 | Rs.270.85 | +23.3% |
Segment and geographic performance
- Global Generics: Revenue of Rs.245,453 million, up 15%; gross profit of Rs.154,268 million and segment gross margin of 62.9%, compared with 62.1% in FY2023.
- North America: Revenue of Rs.129,895 million, up 28% in rupees and 24% in U.S. dollar terms. Growth reflected higher volumes, the Mayne Pharma portfolio acquisition and new products, partly offset by price erosion.
- Europe: Revenue of Rs.20,511 million, up 17%, driven by volume growth and launches, partly offset by pricing pressure.
- India: Revenue of Rs.46,407 million, down 5%, primarily due to the prior-year divestment of non-core brands. Indian secondary sales grew 7.3%, versus 7.6% market growth.
- Russia: Revenue of Rs.22,301 million, up 5% in rupees and 16% in Russian roubles. The company reported continued supply without significant shortages, despite higher freight costs and longer lead times.
- PSAI: Revenue of Rs.29,801 million, up 3%; gross profit of Rs.6,919 million and gross margin of 23.2%, up from 16.2%.
Cash flow, liquidity and debt
| Metric | FY2024 | FY2023 |
|---|---|---|
| Operating cash flow | Rs.45,433 million | Rs.58,875 million |
| Investing cash flow | (Rs.40,283 million) | (Rs.41,373 million) |
| Financing cash flow | (Rs.3,763 million) | (Rs.26,861 million) |
| Net change in cash | Rs.1,387 million | (Rs.9,359 million) |
| Cash and equivalents | Rs.7,107 million | Rs.5,779 million |
| Working capital | Rs.152,010 million | Rs.121,095 million |
- Current investments included Rs.40,597 million in mutual funds and Rs.33,599 million in term deposits, bonds and commercial paper.
- Total principal debt obligations excluding leases were Rs.16,523 million: Rs.12,723 million due within one year and Rs.3,800 million due in two to three years.
- Including lease obligations, total borrowings and lease liabilities were Rs.20,020 million at March 31, 2024.
- Uncommitted bank credit lines were Rs.61,131 million, down from Rs.68,516 million.
- Operating cash flow declined by Rs.13,442 million, primarily because of higher working-capital requirements. Days sales outstanding remained 103 days.
Capital allocation and material changes
- Capital expenditures, net of asset disposals, were Rs.26,350 million, compared with Rs.18,784 million in FY2023. Capital commitments were Rs.18,177 million, with projects primarily supporting injectable, biologics and manufacturing capacity.
- Research and development expense increased 18% to Rs.22,873 million, or 8.2% of revenue.
- SG&A increased 13% to Rs.77,201 million, while remaining 27.7% of revenue.
- Impairment expense fell to Rs.3 million from Rs.699 million. FY2024 included impairment charges for certain products and software platforms, partly offset by reversals related to products launched during the year.
- The company acquired the Mayne Pharma U.S. generic prescription portfolio for net consideration of approximately U.S.$93 million, including product-related intangible assets and inventory.
- The company paid Rs.622 million for an exclusive license from Coya Therapeutics for COYA 302 and acquired the MenoLabs portfolio for Rs.228 million.
- The company invested in renewable-energy projects and entered into a vaccine distribution agreement with Sanofi Healthcare India.
- The Board proposed a final dividend of Rs.40 per share, totaling approximately Rs.6,673 million, subject to shareholder approval. Cash dividends paid during FY2024 were Rs.6,648 million.
Guidance, outlook and management commentary
The filing does not provide formal consolidated financial guidance or quantified revenue or earnings targets. Management describes growth priorities as market leadership, operational excellence and patient-focused innovation. PSAI growth is expected to benefit from investments in technologies such as peptides and expanded partnership activity. The company also intends to finance additional capital expansion primarily through operating cash flows, cash and investments, with borrowings as required.
- As of March 31, 2024, the company had 325 cumulative U.S. ANDA filings and 86 applications pending approval, including 50 Paragraph IV filings and 24 filings it believes were first-to-file.
- The company reported three ongoing biosimilar IND programs and early-stage pre-IND work on four additional molecules.
- In April 2024, the U.S. FDA issued a complete response letter for the rituximab biosimilar BLA, citing resolution of observations from an October 2023 biologics-facility inspection and other BLA matters. Resubmission is planned, but approval and timing remain uncertain.
- Subsequent inspections in May and June 2024 resulted in Form 483 observations at Visakhapatnam formulations facilities and the Srikakulam API facility.
- The company expects a proposed nutraceutical joint venture with Nestlé India to become effective by the quarter ending September 30, 2024, subject to closing conditions. Dr. Reddy’s would initially own 51%.
Risks, contingencies and unusual items
- Major risks include U.S. FDA and other regulatory actions, manufacturing or quality failures, product recalls, supply-chain disruptions, price erosion, generic competition, patent litigation, reimbursement and price controls, and customer concentration.
- North America’s ten largest customers represented approximately 77% of segment revenue; two customers collectively represented approximately 15% of total company revenue.
- Material legal and regulatory matters include ranitidine litigation, U.S. generic-drug antitrust MDL proceedings, Canadian competition litigation, Revlimid antitrust litigation, pricing-related proceedings in India, and other patent and commercial disputes. The filing states that many potential losses are not reasonably estimable and that no provision was recorded for several matters.
- An internal investigation concerning alleged improper payments to healthcare professionals in Ukraine and potentially other countries remains subject to SEC and DOJ inquiries. Possible enforcement outcomes and liabilities are not reasonably ascertainable.
- Environmental matters include historical land-pollution proceedings in India, remediation-related claims and fuel-surcharge disputes. Recorded provisions include Rs.61 million for an environmental liability and Rs.804 million for legal and other matters.
- Geopolitical exposure includes the Russia-Ukraine conflict, Middle East hostilities, sanctions, foreign-exchange volatility, higher freight costs and potential supply interruptions. Management concluded that the FY2024 impact was not material but continues to monitor developments.
- Foreign-exchange sensitivity: a 10% movement in relevant currencies would have affected the hedging reserve by approximately Rs.7,041 million upward or Rs.7,269 million downward, and profit by approximately Rs.2,203 million upward or Rs.2,315 million downward.
- The company reported effective disclosure controls and effective internal control over financial reporting. Ernst & Young Associates LLP issued unqualified audit opinions.
Most important facts for investors to verify
- Confirm that the annual filing is being compared with FY2023 rather than treated as a standalone Q4 2023 report.
- Reconcile revenue growth with the contribution from the Mayne acquisition, volume increases, new launches, foreign exchange and continuing North American and European price erosion.
- Review the sustainability of the 58.6% gross margin and the unusually strong PSAI margin improvement.
- Assess working-capital usage, inventory growth to Rs.63,552 million, receivables of Rs.80,298 million and the decline in operating cash flow.
- Evaluate regulatory remediation, particularly the rituximab CRL, the biologics facility observations and later Form 483 observations.
- Review Note 32 for the estimated exposure, status and potential outcomes of antitrust, patent, pricing, environmental and FCPA-related matters.
- Monitor customer concentration and the effect of generic competition and price erosion on North American profitability.
- Verify shareholder approval and payment timing for the proposed Rs.40-per-share dividend and the subsequent promoter-share transfers from the APS Trust.